Locations:
Search
The new monthly series will focus on cutting-edge medical research and innovative technologies developed at Cleveland Clinic, providing external audiences with insights into the future of healthcare and the opportunity to connect with Cleveland Clinic's visionary inventors.
Cleveland Clinic Innovations portfolio company, Cleveland Diagnostics, launches its second annual prostate-specific antigen campaign “A PSA on PSA” to raise awareness and education for prostate cancer screening tests.
Cleveland Clinic inventors Dianne Perez, PhD, and Shaun Stauffer, PhD, discuss their research’s impact on patient care for Cleveland Clinic Innovations’ Inventor Chronicle series.
Omega Funds and Intuitive Ventures join top-tier syndicate of healthcare investors, including founding investor Cleveland Clinic, to support ongoing clinical activities.
The deal will expand Strolll’s digital therapeutics platform and see Cleveland Clinic become a shareholder in the company. Lead investigator and Cleveland Clinic inventor, Jay Alberts, PhD, Vice Chair of Innovation in Cleveland Clinic’s Neurological Institute, comments.
Under the terms of the $3 million agreement, Cleveland Clinic is taking an equity stake in Strolll. Additionally, a therapeutic tool developed by Cleveland Clinic will be integrated into the Strolll platform.
In the Nurse Inventor Spotlight series, Cleveland Clinic nurses share their innovation journey, inspiration, how they identified unmet needs, and impact on patients and caregivers.
Cleveland Clinic Innovations portfolio company Centerline Biomedical’s Intra-Operative Positioning System (IOPS) aims to help clinicians visualize endovascular tools in real-time and reduce their dependence on fluoroscopy systems.
Bernardo Perez-Villa, MD, MSc, Senior Engagement Partner, Innovations, shares with Cardiac Care three promising technologies poised to reshape how we address cardiovascular diseases. Cleveland Clinic Innovations portfolio companies Advanced NanoTherapies Inc., Cardionomic Inc., and Mitria Medical, are featured.
510(k) clearance by FDA further addresses the market need to reduce physician exposure to harmful x-ray radiation during image-guided, endovascular procedures.